Clinical efficacy and safety of zoledronic acid in prostate and breast cancer

被引：8

作者：

Doggrell, Sheila A. ^{[1
]}

机构：

[1] Queensland Univ Technol, Sch Life Sci, Brisbane, Qld 4001, Australia

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2009年 / 9卷 / 09期

关键词：

bisphosphonates; bone metastases; breast cancer; clinical trials; efficacy; osteoporosis; prostate cancer; zoledronic acid; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS; ANDROGEN DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; BONE METASTASES; POSTMENOPAUSAL WOMEN; SKELETAL COMPLICATIONS; PREVENTIVE MEASURES; MULTIPLE-MYELOMA; JAW; PAIN;

D O I：

10.1586/ERA.09.95

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The anti-estrogen treatment for hormone-sensitive breast cancer and the androgen deprivation therapy for prostate cancer can lead to the development of osteoporosis and bone fractures. Metastases associated with prostate and breast cancer can also occur in bone. Bisphosphonates are used in these types of bone dysfunction. Zoledronic acid is the most potent bisphosphonate. In osteoporosis, zoledronic acid inhibits bone reabsorption and increases bone mineral density for at least a year after intravenous administration. The efficacy and safety of zoledronic acid in osteoporosis secondary to hormone-sensitive cancers (prostate and breast), and in the bone metastases associated with these cancers are reviewed.

引用

页码：1211 / 1218

页数：8

共 61 条

[1]

Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis [J].

Aguiar Bujanda, D. ;

Bohn Sarmiento, U. ;

Cabrera Suarez, M. A. ;

Aguiar Morales, J. .

ANNALS OF ONCOLOGY, 2007, 18 (03) :556-560

[2]

[Anonymous], Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

[3]

Scleritis complicating zoledronic acid infusion [J].

Benderson, David ;

Karakunnel, Joyson ;

Kathuria, Sajeev ;

Badros, Ashraf .

CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (02) :145-147

[4]

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[5]

Current use of bisphosphonates in oncology [J].

Body, JJ ;

Bartl, R ;

Burckhardt, P ;

Delmas, PD ;

Diel, IJ ;

Fleisch, H ;

Kanis, JA ;

Kyle, RA ;

Mundy, GR ;

Paterson, AHG ;

Rubens, RD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) :3890-3899

[6]

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment [J].

Brubaker, KD ;

Brown, LG ;

Vessella, RL ;

Corey, E .

BMC CANCER, 2006, 6 (1)

[7]

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole [J].

Brufsky, Adam ;

Bundred, Nigel ;

Coleman, Robert ;

Lambert-Falls, Rosemary ;

Mena, Raul ;

Hadji, Peyman ;

Jin, Lixian ;

Schenk, Nora ;

Ericson, Solveig ;

Perez, Edith A. .

ONCOLOGIST, 2008, 13 (05) :503-514

[8]

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer [J].

Brufsky, Adam ;

Harker, W. Graydon ;

Beck, J. Thaddeus ;

Carroll, Robert ;

Tan-Chiu, Elizabeth ;

Seidler, Christopher ;

Hohneker, John ;

Lacerna, Leo ;

Petrone, Stephanie ;

Perez, Edith A. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :829-836

[9]

Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results [J].

Brufsky, Adam M. ;

Bosserman, Linda D. ;

Caradonna, Richard R. ;

Haley, Barbara B. ;

Jones, Michael ;

Moore, Halle C. F. ;

Jin, Lixian ;

Warsi, Ghulam M. ;

Ericson, Solveig G. ;

Perez, Edith A. .

CLINICAL BREAST CANCER, 2009, 9 (02) :77-85

[10]

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole [J].

Bundred, Nigel J. ;

Campbell, Ian D. ;

Davidson, Neville ;

DeBoer, Richard H. ;

Eidtmann, Holger ;

Monnier, Alain ;

Neven, Patrick ;

von Minckwitz, Gunter ;

Miller, Joel C. ;

Schenk, Nora L. ;

Coleman, Robert E. .

CANCER, 2008, 112 (05) :1001-1010

← 1 2 3 4 5 6 7 →